Search clinical trials for: VRC07-523LS (1.4g, SC)

Total 19 results

National Institute of Allergy and Infectious Diseases...
National Institutes of Health (NIH); Department of Health and Human Services

Completed

A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants

HIV Infections

United States, Zimbabwe, Kenya, South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants

HIV Infections

United States, Puerto Rico, Zimbabwe, South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants (VRC07-523LS)

HIV Infections

United States
International AIDS Vaccine Initiative
National Institute of Allergy and Infectious Diseases (NIAID); Beth Israel... and other collaborators

Completed

A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults

HIV/AIDS

United States
National Institute of Allergy and Infectious Diseases...

Completed

VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults

HIV Prevention

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults

HIV Infections

United States, Switzerland
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network; HIV Prevention Trials Network

Completed

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults

Healthy Adult Immune Response

United States
David Ho
US Military HIV Research Program; Henry M. Jackson Foundation for the Advancement... and other collaborators

Recruiting

10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults

HIV-1-infection

Tanzania
National Institute of Allergy and Infectious Diseases...
ImmunityBio, Inc.; Rockefeller University

Recruiting

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

HIV Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults

HIV-1

United States, Puerto Rico
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons

HIV-1 Infection

United States
National Institute of Allergy and Infectious Diseases...

Not yet recruiting

A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

Acute HIV Infection

United States, Brazil, Peru
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults

HIV Infections

United States
Boris Juelg, MD PhD
National Institute of Allergy and Infectious Diseases (NIAID); The University... and other collaborators

Recruiting

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

Acquired Immunodeficiency Syndrome | Sexually Transmitted Diseases, Viral | Retroviridae Infections | HIV | Immunologic Deficiency Syndrome, Acquired

United States
Henry M. Jackson Foundation for the Advancement...
US Military HIV Research Program; Janssen Vaccines & Prevention B.V.

Withdrawn

Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission (RV582)

HIV-1-infection

Thailand
International AIDS Vaccine Initiative
Beth Israel Deaconess Medical Center; Ragon Institute of MGH, MIT and Harvard; University of Texas Health, Houston AIDS Research Team (HART) and other collaborators

Completed

A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare

Completed

Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

HIV Infections

United States, Puerto Rico

3

Subscribe